Video Library
World Heart Federation Roadmap
In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the World Heart Foundation’s Cholesterol Roadmap (2022) for the management and prevention of atherosclerotic cardiovascular disease (ASCVD). He discusses various approaches for ASCVD prevention, emphasizes regional differences in adherence to ASCVD treatment guidelines, and highlights barriers to effective risk management. This roadmap offers a scientifically sound foundation for policymakers to implement changes aimed at reducing the burden of ASCVD.
Prof. Christopher Cannon
First published: August 1, 2024
Running time: 58 minutes, 46 seconds
01.28 Concept of cumulated LDL exposure (mg-years)
05.11 Re-defining secondary prevention
08.04 Early secondary prevention
11.27 Late secondary prevention (CHD)
19.17 Late secondary prevention (PAD)
20.15 Very late secondary prevention (ACS)
23.18 Longer is better
24.55 Earlier is better
26.21 Younger is better
28.39 Older Adults also deserve treatment
41.12 Audience Q&A
Video Library
“Lower, Longer, Sooner, Earlier, and Younger”: Do we have enough evidence?
Prof. Chiang discusses Atherosclerotic Cardiovascular Disease (ASCVD) in context of cumulated LDL exposure, and the different stages of secondary prevention and how starting to manage the disease at a younger age or earlier stage is beneficial. At 41:12 he answers audience questions.
First published: October 25, 2023
Running time: 35 minutes, 49 seconds
00.00 Patients and plaque
03.30 Pictorial representation and
primary prevention or adherence07.00 Calcium Scoring
13.00 Other targets: Lp(a)
21.00 Triglycerides
28.00 Special: Latest data from ESC
Video Library
ASCVD Roundtable Part 2: Other targets and ESC 2023 Highlights
In this second part of the Round Table conversation, the Editorial Panel discuss how showing patients’ images of their plaques help with adherence, discuss other targets such as Lp (a) and triglycerides and most importantly, discuss some of the latest data from the recently concluded ESC congress.
Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt
First published: September 1, 2023
Running time: 25 minutes, 25 seconds
00.00 Introduction
01.21 LDL target and guidelines
07.55 Should we start combination
therapy early?12.35 Side effects of combination
therapy?16.40 Dosing in combination
therapy – InclisiranVideo Library
ASCVD Roundtable Part 1: Target guidelines, dosing, and compliance in lipid lowering therapies
In recognition of the ASCVD & Lipidology Knowledge Hub 2 year anniversary, the esteemed faculty members for this educational resource site met to discuss the hot topics that have occurred over this time. Come and take a seat at this roundtable discussion with Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, and Prof. Deepak Bhatt as they discuss target guidelines, dosing, and compliance in lipid lowering therapies.
Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt
First published: August 1, 2023
Video Library
The SANTORINI Study: Why Are Lipid Control Therapies Not Working?
In this video, we summarize the results from the SANTORINI trial which documents the effectiveness of current treatment practice in managing LDL-C levels for patients in the higher CV risk categories in and how care may be improved.
First published: July 12, 2023
Video Library
The GOULD Registry: Insights into lipid lowering
Prof. Christopher Cannon discusses insights obtained from the GOULD study on how lipids are managed in real-world clinical practice among patients with atherosclerotic cardiovascular disease (ASCVD).
This webinar recording is designed for health care professionals (cardiologists, endocrinologists, lipidogists, diabetes specialists, neurologists) who are interested in learning more on the latest research, treatment, and clinical management of patients with a history and risk of ASCVD.
Prof. Christopher Cannon
First published: June 6, 2023
Video Library
Acute Coronary Syndrome Secondary Prevention – never too early, always too late
In this KOL master class on demand video Prof. Samer Ellahham discusses the secondary prevention of acute coronary syndrome (ACS). He is joined by Prof. Hani Sabbour for a peer-to-peer discussion and to answer audience questions.
This interactive webinar is designed for health care professionals (cardiologists, endocrinologists, lipidologists, neurologists) who are interested in learning more on the latest research, treatment, and clinical management of patients with acute coronary syndrome.
Prof. Samer Ellahham, Prof. Hani Sabbour
First published: February 28, 2023
Video Library
Lipid Measurement Guidelines: NLA Statement Highlights
A Peer-to-Peer Discussion
In this specially compiled video, Dr. Carl Orringer, a past president of the National Lipid Association (NLA), shares his views on the recently published NLA Scientific Statement on Lipid Measurements in the Management of Cardiovascular Diseases in a conversation with our Editorial Panel Member, Prof. Lale Tokgözoğlu. The experts discuss the importance of these lipoprotein measurements to clinicians and other healthcare professionals providing treatment and the importance of shared decision making (SDM) in improving patient care.
Prof. Lale Tokgözoğlu, Dr. Carl Orringer
First published: October 21, 2021
Video Library
Highlights from ESC Congress 2021: Part One
A comprehensive summary of the highlights from ESC Congress 2021 in ASCVD and lipidology. In this specially compiled video, Professor Cannon and Professor Bhatt share their views on the late breaker results from REDUCE-IT and OMENI trials, along with the update ESC prevention guidelines.
Christopher Cannon, MD & Dr. Deepak L. Bhatt MD, MPH
First published: September 16, 2021
Video Library
Highlights from ESC Congress 2021: Part Two
In this second video from the ESC 2021, Professor Cannon and Professor Nicholls discuss late-breaking results from the HUGYENs trial on evolcoumab, as well as the ESC prevention guidelines and the impact of the NHS approval of Inclisiran in improving patient care.
Christopher Cannon, MD & Professor Stephen Nicholls, MBBS, Ph.D., FRACP, FACC, FESC, FAHA, FCSANZ, FAHMS
First published: September 15, 2021